Market Overview

UPDATE: Morgan Stanley Reiterates on Chimerix as New AdV Trial Highlights Broad Brincidofovir Potential


In a report published Wednesday, Morgan Stanley analyst David Friedman reiterated an Overweight rating on Chimerix (NASDAQ: CMRX), but removed the $34.00 price target.

In the report, Morgan Stanley noted, “Chimerix announced today that based on urgent patient need, they have negotiated with the FDA to immediately start an open label 20 pt adenovirus (AdV) trial. Furthermore, the company notes that the FDA has agreed to work with them towards expanding this open label trial into a more comprehensive, pivotal Ph 3 AdV trial. We view this as a good outcome for the company and pts, and reinforces our view that this drug likely has broader potential beyond the recent focus on CMV prevention in high risk stem cell transplants (SCT).”

Chimerix closed on Tuesday at $20.80.

Latest Ratings for CMRX

Jan 2021HC Wainwright & Co.MaintainsBuy
Mar 2019CitigroupMaintainsNeutralNeutral
Feb 2018JP MorganDowngradesNeutralUnderweight

View More Analyst Ratings for CMRX
View the Latest Analyst Ratings


Related Articles (CMRX)

View Comments and Join the Discussion!

Posted-In: David Friedman Morgan StanleyAnalyst Color Price Target Analyst Ratings

Latest Ratings

MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at